FDA Green-Lights Stomach-Stitching Weight-Loss Gadget
Published Date: 5/28/2026
Rule
Summary
The FDA is officially classifying the endoscopic suturing device for weight loss as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative tool faster and ensures it’s safe and effective. The new rules took effect on May 28, 2026, and could save time and money for makers and users alike.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Class II Ruling Speeds Patient Access
The FDA classified the endoscopic suturing device for altering gastric anatomy for weight loss into Class II (special controls), effective May 28, 2026, with the classification applicable July 12, 2022. FDA says this lowers regulatory burden compared with automatic Class III assignment and will enhance patient access to the device and similar innovations.
510(k) Premarket Filing Required
The device is subject to premarket notification requirements under section 510(k) of the FD&C Act and FDA has not exempted it. If you plan to market this device, you must submit a 510(k) premarket notification to FDA before marketing.
Mandatory Testing, Training, Labeling Rules
Manufacturers must meet special controls including clinical performance testing (weight change and all adverse events), non-clinical bench testing (functional, dimensional, tensile), shelf-life and sterility data, biocompatibility, user training, and labeling that summarizes clinical performance and shelf life. These requirements are part of the Class II special controls codified at 21 CFR 876.5983.
De Novo Classification Creates Predicate Pathway
FDA classified the device via the De Novo process, meaning this device type can serve as a predicate for future devices; other sponsors can then use the less-burdensome 510(k) route rather than De Novo or PMA for substantially equivalent devices. The De Novo process requires FDA to issue a classification order within 120 days under the statute.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-10612, Special Local Regulation; Sail Grand Prix, Upper Bay, New York City, NY
The Coast Guard is setting up a temporary no-go zone in Upper Bay, NYC, for the Sail Grand Prix sailboat race on May 30-31, 2026. Boats and people can’t enter the race area during race hours unless they get special permission. This keeps everyone safe while the super-fast boats zoom around and thousands of fans watch.
Next: 2026-10675, Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.